The adverse effects profile of levetiracetam in epilepsy: a more detailed look

References

• Crepeau AZ, Treiman DM. Levetiracetam: a comprehensive review. Expert Rev Neurotherapeutics 2010;10(2):159–71.
   PubMed Web of Science ®Google Scholar
• NICE. National Institute for Clinical Excellence. NICE Clinical Guideline 137. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, January 2012. www.guidance.nice.org.uk /CG137 (accessed 3 August 2012).
   Google Scholar
• Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf 2007;6(3):241–50.
   PubMed Web of Science ®Google Scholar
• Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004;3(5):415–24.
   PubMedGoogle Scholar
• French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res [Comparative Study Research Support, Non-U.S. Gov't Review]. 2001;47(1–2):77–90.
   Google Scholar
• Harden C. Safety profile of levetiracetam. Epilepsia 2001;42(4):36–9.
   PubMedGoogle Scholar
• Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 2012;9:CD001901.
   Google Scholar
• Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41(10):1276–83.
   PubMed Web of Science ®Google Scholar
• Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure-Eur J Epilep 2000;9(2):80–7.
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55(2):236–42.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Ayala R, Elterman RD, Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66(11):1654–60.
   PubMed Web of Science ®Google Scholar
• Levisohn PM, Mintz M, Hunter SJ, Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009;50(11):2377–89.
   PubMed Web of Science ®Google Scholar
• Peltola J, Coetzee C, Jimenez F, Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: A double-blind, randomized, placebo-controlled trial. Epilepsia 2009;50(3):406–14.
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Lowenthal A, Janz D, Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41(9):1179–86.
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Yen DJ, Hsih MS, Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006;47(1):72–81.
   PubMed Web of Science ®Google Scholar
• Wu XY, Hong Z, Wu X, Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 2009;50(3):398–405.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Li JM, Wang XF, Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures. Eur Neurol 2009;61(4):233–9.
   PubMed Web of Science ®Google Scholar
• Schünemann H BeJ, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group, 2009. Available from www.cc-ims.net/gradepro (accessed 3 August 2012).
   Google Scholar
• Zhou B, Zhang Q, Tian LY, Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 2008;12(2):305–10.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs 2011;25(10):901–5.
   PubMed Web of Science ®Google Scholar
• Keppra (levetiracetam 250, 750 and 1000 mg tablets and lOOmg/mL concentrate for solution of infusion): summary of product characteristics. London: European Medicines Agency, 2011.
   Google Scholar
• Cramer JA, De Rue K, Devinsky O, A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2003;4(2): 124–32.
   Google Scholar
• Morrell MJ, Leppik I, French J, The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res [Clinical Trial Clinical Trial, Phase IV Multicenter Study]. 2003;54(2–3):153–61.
   Google Scholar
• Verrotti A, D'Adamo E, Parisi P, Levetiracetam in childhood epilepsy. Paediatr Drugs 2010;12(3):177–86.
   PubMedGoogle Scholar
• Gustafson MC RF, Frost MD, : Behavioral and emotional effects of levetiracetam in children with intractable epilepsy. Epilepsia 2002;43(7):S58.
   Google Scholar
• Kugler SL PI, Mandelbaum DE. Behavioral profile of Levetiracetam in children. Epilepsia (2002)43(7):S59.
   Google Scholar
• White JR, Walczak TS, Leppik IE, Discontinuation of levetiracetam because of behavioral side effects - A case-control study. Neurology 2003;61(9):1218–21.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Arrigo C, Van Hammee G, Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000;41(7):868–74.
   PubMed Web of Science ®Google Scholar
• de la Loge C, Hunter SJ, Schiemann J, Yang HC. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010;18(3): 291–8.
   PubMed Web of Science ®Google Scholar